Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1

NCT02600429 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Neurotrophic Keratopathy

Interventions

DRUG: RGN-259
DRUG: Placebo

Sponsor

ReGenTree, LLC